AbbVie’s investigational drug tavapadon, a D1/D5 dopamine receptor partial agonist, demonstrated positive results in a Phase 3 trial for early Parkinson’s disease. The drug showed a statistically significant improvement in motor function and quality of life compared to placebo in patients with early Parkinson’s disease.